A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression. Their work was published this week in NEJM Evidence.
New clinical tool for clonal hematopoiesis identifies patients at high risk for blood cancer
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression. Their work was published this week in NEJM Evidence.